BÜHLMANN has been the market leading provider of faecal calprotectin assays in the UK for over 10 years, holding a significant portion of the market share, as recorded on the National External Quality Assurance Scheme (NEQAS).
The BÜHLMANN results are split across the two main laboratory assays: fCAL ELISA and fCAL turbo assays. There is also some contribution from the IBDoc patient self-test assay.
The current report format shows the data split out by method with 20 participants for fCAL ELISA, 26 participants for fCAL turbo and one participant for IBDoc in November 2021.
The BÜHLMANN fCAL® turbo assay allows very rapid and flexible random access use, as well as being the ideal solution for high throughput applications in the routine laboratory.
With it’s successful roll out over the last few years there are now 26 routine users on the UK NEQAS. These cover all the main clinical chemistry analyser systems including Abbott, Beckman, Roche and Siemens including all the various different models they have.
More Detailed Reporting by Test Platform
As part of some wider discussions with the Birmingham Quality UK NEQAS team (Finlay MacKenzie, Rachel Marrington and Martin Roch), it was thought to be a good idea to give their participants some additional information by asking on what platform fCAL turbo assays are being performed.
This will allow fCAL turbo results to be broken down, and means provided, at the manufacturer level.
Depending on the numbers of users for a manufacturer, it may be possible to further breakdown by analyser/platform in due course. Their USP Rainbow Trout Plot of interpretations versus concentration for each method will remain at the overall fCAL turbo level.
Existing participants in their Scheme will be aware that the fCAL turbo is currently listed as a single method.
For more information, visit the Birmingham Quality website: birminghamquality.org.uk
